In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Ullrich, Roland T ^a,b,c   Jikeli, Jan F ^a   Diedenhofen, Michael ^a   Böhm Sturm, Philipp ^a   Unruh, Maike ^a   Vollmar, Stefan ^a   Hoehn, Mathias ^a  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b Center for Molecular Medicine   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE; VATALANIB; ANGIOGENESIS INHIBITOR; PHTHALAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; IMAGE ANALYSIS; IMAGE QUALITY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VALIDATION PROCESS; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG SCREENING; HUMAN; MICROVASCULATURE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICROVESSELS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955797422     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019592     Document Type: Article

References (25)

1. Folkman J, (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
2. Carmeliet P, (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
3. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, et al. (2009) Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27: 4718-4726.
4. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, et al. (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25: 3045-3054.
5. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, et al. (1998) NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40: 793-799.
6. Jensen JH, Chandra R, (2000) MR imaging of microvasculature. Magn Reson Med 44: 224-230.
7. Eis M, Els T, Hoehn-Berlage M, (1995) High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magn Reson Med 34: 835-844.
8. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, et al. (2008) Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3: e3908.
9. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, et al. (2004) Fast and robust registration of PET and MR images of human brain. Neuroimage 22: 434-442.
10. Tropres I, Grimault S, Vaeth A, Grillon E, Julien C, et al. (2001) Vessel size imaging. Magn Reson Med 45: 397-408.
11. Kiselev VG, Posse S, (1999) Analytical model of susceptibility-induced MR signal dephasing: effect of diffusion in a microvascular network. Magn Reson Med 41: 499-509.
12. Kiselev VG, (2010) Spin Echo Amplitude in Biological Tissue with Implications for Vessel Size Imaging. Joint Annual Meeting ISMRM-ESMRMB, Stockholm (01-07052010) 1: 1792 (Proc.).
13. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, et al. (2009) Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 29: 1125-1133.
14. Ivy SP, Wick JY, Kaufman BM, (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6: 569-579.
15. Jensen JH, Lu H, Inglese M, (2006) Microvessel density estimation in the human brain by means of dynamic contrast-enhanced echo-planar imaging. Magn Reson Med 56: 1145-1150.
16. Wu EX, Tang H, Jensen JH, (2004) High-resolution MR imaging of mouse brain microvasculature using the relaxation rate shift index Q. NMR Biomed 17: 507-512.
17. Lin CY, Chang C, Cheung WM, Lin MH, Chen JJ, et al. (2008) Dynamic changes in vascular permeability, cerebral blood volume, vascular density, and size after transient focal cerebral ischemia in rats: evaluation with contrast-enhanced magnetic resonance imaging. J Cereb Blood Flow Metab 28: 1491-1501.
18. Drevs J, Muller-Driver R, Wittig C, Fuxius S, Esser N, et al. (2002) PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-4022.
19. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
20. Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, et al. (2008) Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed 21: 1021-1029.
21. Valonen PK, Lehtimaki KK, Vaisanen TH, Kettunen MI, Grohn OH, et al. (2004) Water diffusion in a rat glioma during ganciclovir-thymidine kinase gene therapy-induced programmed cell death in vivo: correlation with cell density. J Magn Reson Imaging 19: 389-396.
22. Chenevert TL, McKeever PE, Ross BD, (1997) Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3: 1457-1466.
23. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, et al. (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102: 16759-16764.
24. Schwarz AJ, Reese T, Gozzi A, Bifone A, (2003) Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn Reson Imaging 21: 1191-1200.
25. Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, et al. (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248: 799-806.